Premier Diagnostics designs, finances and operates diagnostic imaging centers in Canada and China. The Company specializes in PET/CT and MRI imaging to assist doctors in the detection, evaluation and establishment of the most effective treatments for cancer (oncology), certain diseases of the heart (cardiology), and brain disorders (neurology). The Company's mission is to become the premier public / private provider of medical diagnostic services in China, expanding upon our very successful Beijing MRI and Vancouver PET/CT models.
Premier Diagnostic Center – Burnaby
PET/CT in Canada
In B.C. an estimated 23,700 people were diagnosed with cancer in 2013 of which at least 10,000 could benefit from PET/CT. Our medical system capacity is approximately 3,000 scans on each of the two scanners at the BC Cancer Agency's Vancouver facility. These government figures demonstrate the potential demand for PET/CT.
In addition, as a private facility we have attracted the attention of researchers across the country. We will soon be embarking on new clinical trials including an Alzheimer's and Parkinson's PET research study, as well as a choline based PET pharmaceutical trial for advanced pancreatic, prostate, and colorectal imaging.
Premier Diagnostic Centers – China
Premier Diagnostic Health
We are developing and operating diagnostic imaging clinics in China, providing advanced imaging technology that improves patient treatment and outcomes.
The Chinese middle class is expanding at a rapid rate, increasing discretionary spending ability, which includes demand for a wide range of Western medical diagnostic services. The central government has recognized this trend and recently has encouraged direct foreign investment in the health care sector. Accordingly, there is an increased demand for PET/CT, the gold standard in cancer detection, and high-end MRI.
Our China MRI Center in Beijing has exceeded our goals and expectations due to our efficient management protocols and huge demand, exceeding 1100 scans per month in 2014.
Sequant Re Holdings
Sequant Re provides reinsurance brokers and buyers of reinsurance access to flexible collateralised reinsurance and retrocession solutions for their risk transfer needs. We are able to provide peace of mind fully collateralised protection at efficient costs for deals of all sizes.
For investors, the emerging convergence market offers a broad spectrum of opportunities for diversifying returns. Sequant Re will guide investors into the selection of the right transactions for their risk tolerance and yield expectations. Investors with Sequant Re’s platform benefit from lower cost of execution, lower barriers to entry, and portfolio management options.
Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) (CSE: PDH) is pleased to announce a non-brokered private placement offering (the “Offering”) of common shares...
PREMIER DIAGNOSTIC HEALTH SERVICES INC. ANNOUNCES NEW PRESIDENT AND CEO Premier Diagnostic Health Services Inc. (“Premier” or the “Company“) (CSE: PDH) is pleased to announce...
Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) announces that the Board of Directors has appointed distinguished clinician and scientist Dr. Simon Sutcliffe, M.D.,...
Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) is pleased to announce the appointment of a new member to its board of directors and...